Abstract
A deficiency of central neural transmission mediated by acetylcholine (ACh) is implicated in the etiopathology of Alzheimer's disease. The appreciation of this neurochemical deficit has led to treatment strategies designed to facilitate central cholinergic transmission (1). A major limitation of current clinical studies is the availability of centrally-effective, long-acting cholinomimetic agents. This situation has led to the search for such agents.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
